Induction and maintenance treatment of inflammatory bowel disease

A comprehensive review

Dong Yeon Jeong, Seung Kim, Min Ji Son, Chei Yun Son, Jong Yeob Kim, Andreas Kronbichler, Keum Hwa Lee, Jaeil Shin

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Ulcerative colitis (UC) and Crohn's disease (CD) are the two major types of inflammatory bowel disease (IBD). We conducted a comprehensive review of meta-analyses to summarize the reported effectiveness of different drugs for IBD. We performed a literature search and a total of 110 meta-analyses from 66 articles were summarized and re-analyzed (62 in UC and 48 in CD). In summary, 5-ASA was more effective than placebo in both induction and maintenance treatment of UC, but there were conflicting results on the effect of 5-ASA on the induction treatment or relapse of CD. The use of immunomodulatory agents in the induction or maintenance phase of UC and CD using immunomodulators appeared to be more effective than placebo, but the results were impacted by small number of patients, discordant results with the largest study and risk of biases. Anti-TNF-α and anti-integrin therapeutic antibodies in both, induction and maintenance, showed a better efficacy than placebo in a large proportion of patients analyzed. Other agents, such as probiotics, antibiotics, omega-3, were shown to be more effective than placebo, but the same issues arose as stated above with the use of immunomodulatory agents. In conclusion, we performed a comprehensive review of meta-analysis on comparative efficacy of pharmacotherapy used in the management of IBD. Our review will augment our understanding of the treatment of UC and CD by providing a guideline for interpreting the statistically significant findings and discusses the optimal choice for IBD treatment.

Original languageEnglish
Pages (from-to)439-454
Number of pages16
JournalAutoimmunity Reviews
Volume18
Issue number5
DOIs
Publication statusPublished - 2019 May 1

Fingerprint

Ulcerative Colitis
Inflammatory Bowel Diseases
Crohn Disease
Placebos
Meta-Analysis
Maintenance
Therapeutics
Probiotics
Immunologic Factors
Integrins
Guidelines
Anti-Bacterial Agents
Recurrence
Drug Therapy
Antibodies
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Jeong, Dong Yeon ; Kim, Seung ; Son, Min Ji ; Son, Chei Yun ; Kim, Jong Yeob ; Kronbichler, Andreas ; Lee, Keum Hwa ; Shin, Jaeil. / Induction and maintenance treatment of inflammatory bowel disease : A comprehensive review. In: Autoimmunity Reviews. 2019 ; Vol. 18, No. 5. pp. 439-454.
@article{f70cd62c62f543abb93e07e379eca730,
title = "Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review",
abstract = "Ulcerative colitis (UC) and Crohn's disease (CD) are the two major types of inflammatory bowel disease (IBD). We conducted a comprehensive review of meta-analyses to summarize the reported effectiveness of different drugs for IBD. We performed a literature search and a total of 110 meta-analyses from 66 articles were summarized and re-analyzed (62 in UC and 48 in CD). In summary, 5-ASA was more effective than placebo in both induction and maintenance treatment of UC, but there were conflicting results on the effect of 5-ASA on the induction treatment or relapse of CD. The use of immunomodulatory agents in the induction or maintenance phase of UC and CD using immunomodulators appeared to be more effective than placebo, but the results were impacted by small number of patients, discordant results with the largest study and risk of biases. Anti-TNF-α and anti-integrin therapeutic antibodies in both, induction and maintenance, showed a better efficacy than placebo in a large proportion of patients analyzed. Other agents, such as probiotics, antibiotics, omega-3, were shown to be more effective than placebo, but the same issues arose as stated above with the use of immunomodulatory agents. In conclusion, we performed a comprehensive review of meta-analysis on comparative efficacy of pharmacotherapy used in the management of IBD. Our review will augment our understanding of the treatment of UC and CD by providing a guideline for interpreting the statistically significant findings and discusses the optimal choice for IBD treatment.",
author = "Jeong, {Dong Yeon} and Seung Kim and Son, {Min Ji} and Son, {Chei Yun} and Kim, {Jong Yeob} and Andreas Kronbichler and Lee, {Keum Hwa} and Jaeil Shin",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.autrev.2019.03.002",
language = "English",
volume = "18",
pages = "439--454",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "5",

}

Jeong, DY, Kim, S, Son, MJ, Son, CY, Kim, JY, Kronbichler, A, Lee, KH & Shin, J 2019, 'Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review', Autoimmunity Reviews, vol. 18, no. 5, pp. 439-454. https://doi.org/10.1016/j.autrev.2019.03.002

Induction and maintenance treatment of inflammatory bowel disease : A comprehensive review. / Jeong, Dong Yeon; Kim, Seung; Son, Min Ji; Son, Chei Yun; Kim, Jong Yeob; Kronbichler, Andreas; Lee, Keum Hwa; Shin, Jaeil.

In: Autoimmunity Reviews, Vol. 18, No. 5, 01.05.2019, p. 439-454.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Induction and maintenance treatment of inflammatory bowel disease

T2 - A comprehensive review

AU - Jeong, Dong Yeon

AU - Kim, Seung

AU - Son, Min Ji

AU - Son, Chei Yun

AU - Kim, Jong Yeob

AU - Kronbichler, Andreas

AU - Lee, Keum Hwa

AU - Shin, Jaeil

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Ulcerative colitis (UC) and Crohn's disease (CD) are the two major types of inflammatory bowel disease (IBD). We conducted a comprehensive review of meta-analyses to summarize the reported effectiveness of different drugs for IBD. We performed a literature search and a total of 110 meta-analyses from 66 articles were summarized and re-analyzed (62 in UC and 48 in CD). In summary, 5-ASA was more effective than placebo in both induction and maintenance treatment of UC, but there were conflicting results on the effect of 5-ASA on the induction treatment or relapse of CD. The use of immunomodulatory agents in the induction or maintenance phase of UC and CD using immunomodulators appeared to be more effective than placebo, but the results were impacted by small number of patients, discordant results with the largest study and risk of biases. Anti-TNF-α and anti-integrin therapeutic antibodies in both, induction and maintenance, showed a better efficacy than placebo in a large proportion of patients analyzed. Other agents, such as probiotics, antibiotics, omega-3, were shown to be more effective than placebo, but the same issues arose as stated above with the use of immunomodulatory agents. In conclusion, we performed a comprehensive review of meta-analysis on comparative efficacy of pharmacotherapy used in the management of IBD. Our review will augment our understanding of the treatment of UC and CD by providing a guideline for interpreting the statistically significant findings and discusses the optimal choice for IBD treatment.

AB - Ulcerative colitis (UC) and Crohn's disease (CD) are the two major types of inflammatory bowel disease (IBD). We conducted a comprehensive review of meta-analyses to summarize the reported effectiveness of different drugs for IBD. We performed a literature search and a total of 110 meta-analyses from 66 articles were summarized and re-analyzed (62 in UC and 48 in CD). In summary, 5-ASA was more effective than placebo in both induction and maintenance treatment of UC, but there were conflicting results on the effect of 5-ASA on the induction treatment or relapse of CD. The use of immunomodulatory agents in the induction or maintenance phase of UC and CD using immunomodulators appeared to be more effective than placebo, but the results were impacted by small number of patients, discordant results with the largest study and risk of biases. Anti-TNF-α and anti-integrin therapeutic antibodies in both, induction and maintenance, showed a better efficacy than placebo in a large proportion of patients analyzed. Other agents, such as probiotics, antibiotics, omega-3, were shown to be more effective than placebo, but the same issues arose as stated above with the use of immunomodulatory agents. In conclusion, we performed a comprehensive review of meta-analysis on comparative efficacy of pharmacotherapy used in the management of IBD. Our review will augment our understanding of the treatment of UC and CD by providing a guideline for interpreting the statistically significant findings and discusses the optimal choice for IBD treatment.

UR - http://www.scopus.com/inward/record.url?scp=85063129229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063129229&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2019.03.002

DO - 10.1016/j.autrev.2019.03.002

M3 - Review article

VL - 18

SP - 439

EP - 454

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 5

ER -